PRODUCT INFORMATION



L-161,982

Item No. 10011565

CAS Registry No.:	147776-06-5	
Formal Name:	N-[[4'-[[3-butyl-1,5-dihydro-5-	
	oxo-1-[2-(trifluoromethyl)phenyl]-	\setminus _/
	4H-1,2,4-triazol-4-yl]methyl]	
	[1,1'-biphenyl]-2-yl]sulfonyl]-3-	$N - N CF_3$
	methyl-2-thiophenecarboxamide	$\sim \wedge / \downarrow \rightarrow \circ$
MF:	$C_{32}H_{29}F_{3}N_{4}O_{4}S_{2}$	
FW:	654.7	
Purity:	≥95%	S' T
UV/Vis.:	λ _{max} : 249 nm	
Supplied as:	A crystalline solid	Ť Ĭ
Storage:	-20°C	
Stability:	≥4 years	~

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

L-161,982 is supplied as a crystalline solid. A stock solution may be made by dissolving the L-161,982 in an organic solvent purged with an inert gas. L-161,982 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of L-161,982 in these solvents is approximately 10 mg/ml.

If aqueous stock solutions are required for biological experiments, they can best be prepared by diluting the organic solvent into aqueous buffers or isotonic saline. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

Prostaglandin E_2 (PGE₂) exerts its effects through four separate G coupled-protein receptors (EP₁₋₄).¹ L-161,982 is a potent and selective EP_4 receptor antagonist. It demonstrates selective binding to human EP_4 receptors with a K₁ value of 0.024 μ M compared to other receptors of the prostanoid family, EP₁, EP₂, EP₃, DP, FP, and IP, with K_i values of 17, 23, 1.9, 5.1, 5.6, and 6.7 µM, respectively.² L-161,982 at 10 mg/kg/day suppresses PGE_2 -stimulated bone formation in young rats² and at 100 nM reverses the anti-inflammatory action of PGE_2 in LPS-activated human macrophages.³ At 10 μ M L-161,982 blocks PGE_2 -induced cell proliferation in HCA-7 colon cancer cells.⁴

References

- 1. Coleman, R.A., Smith, W.L., and Narumiya, S. Pharmacol. Rev. 46(2), 205-229 (1994).
- 2. Machwate, M., Harada, S., Leu, C.T., et al. Mol. Pharmacol. 60(1), 36-41 (2001).
- 3. Takayama, K., García-Gardeña, G., Sukhova, G.K., et al. J. Biol. Chem. 277(46), 44147-44154 (2002).
- 4. Cherukuri, D.P., Chen, X.B.O., Goulet, A.-C., et al. Exp. Cell Res. 313(14), 2969-2979 (2007).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM